Merck & Company – Consensus Indicates Potential 9.7% Upside

Broker Ratings

Merck & Company with ticker code (MRK) now have 23 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 135 and 96 calculating the mean target price we have 118.09. Given that the stocks previous close was at 107.68 this now indicates there is a potential upside of 9.7%. The day 50 moving average is 109.29 while the 200 day moving average is 96.61. The company has a market cap of $270,045m. You can visit the company’s website by visiting:

The potential market cap would be $296,152m based on the market concensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Merck & Co. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences to jointly develop and commercialize long-acting treatments in HIV. Merck & Co. also has a strategic research collaboration agreement with Aqilion AB to discover, develop, and commercialize small molecule inhibitors of the transforming growth factor-ß-activated kinase 1 (TAK1) protein. Merck & Co. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:

    Forum friendly shortlink:

      AIM All Share Index